Combining Enzalutamide with Abiraterone, Prednisone, and Androgen Deprivation Therapy in the STAMPEDE Trial

被引：48

作者：

Attard, Gerhardt ^{[1
,2
,3
]}

Sydes, Matthew R. ^{[4
]}

Mason, Malcolm D. ^{[5
]}

Clarke, Noel W. ^{[6
]}

Aebersold, Daniel ^{[7
]}

de Bono, Johann S. ^{[1
,2
,3
]}

Dearnaley, David P. ^{[1
,2
,3
]}

Parker, Chris C. ^{[1
,2
,3
]}

Ritchie, Alastair W. S. ^{[4
]}

Russell, J. Martin ^{[8
]}

Thalmann, George ^{[9
]}

Cassoly, Estelle ^{[10
]}

Millman, Robin

Matheson, David

Schiavone, Francesca ^{[4
]}

Spears, Melissa R. ^{[4
]}

Parmar, Mahesh K. B. ^{[4
]}

James, Nicholas D. ^{[11
]}

机构：

[1] Inst Canc Res, London SW3 6JB, England

[2] Royal Marsden NHS Fdn Trust, London, England

[3] Royal Marsden NHS Fdn Trust, Sutton, Surrey, England

[4] UCL, MRC, Clin Trials Unit, London, England

[5] Cardiff Univ, Sch Med, Velindre Hosp, Cardiff CF10 3AX, S Glam, Wales

[6] Christie NHS Fdn Trust, Dept Urol, Manchester, Lancs, England

[7] Univ Bern, Bern, Switzerland

[8] Univ Glasgow, Inst Canc Sci, Glasgow, Lanark, Scotland

[9] Univ Hosp Bern, Dept Urol, CH-3010 Bern, Switzerland

[10] Swiss Grp Clin Canc Res SAKK, Bern, Switzerland

[11] Univ Warwick, Warwick, England

来源：

EUROPEAN UROLOGY | 2014年 / 66卷 / 05期

关键词：

METASTATIC PROSTATE-CANCER; INCREASED SURVIVAL; INHIBITOR; RECEPTOR; ACETATE;

D O I：

10.1016/j.eururo.2014.05.038

中图分类号：

R5 [内科学]; R69 [泌尿科学（泌尿生殖系疾病）];

学科分类号：

1002 ; 100201 ;

摘要：

引用

页码：799 / 802

页数：4

共 50 条

[41] Cost-effectiveness of enzalutamide versus apalutamide versus androgen deprivation therapy alone for the treatment of metastatic castration-sensitive prostate cancer in Canada
Saad, Fred
Chilelli, Andrew
Hui, Benny
Muratov, Sergey
Ganguli, Arijit
North, Scott
Shayegan, Bobby
JOURNAL OF MEDICAL ECONOMICS, 2022, 25 (01) : 583 - 590
[42] KEYNOTE-991: pembrolizumab plus enzalutamide and androgen deprivation for metastatic hormone-sensitive prostate cancer
Gratzke, Christian
Kwiatkowski, Mariusz
Giorgi, Ugo De
Martins da Trindade, Karine
De Santis, Maria
Armstrong, Andrew J.
Niu, Cuizhen
Liu, Yingjie
Poehlein, Christian Heinrich
FUTURE ONCOLOGY, 2022, 18 (37) : 4079 - 4087
[43] Economic Outcomes in Patients with Chemotherapy-Naive Metastatic Castration-Resistant Prostate Cancer Treated with Enzalutamide or Abiraterone Acetate Plus Prednisone
Ramaswamy, Krishnan
Lechpammer, Stanislav
Mardekian, Jack
Huang, Ahong
Schultz, Neil M.
Sandin, Rickard
Wang, Li
Baser, Onur
George, Daniel J.
ADVANCES IN THERAPY, 2020, 37 (05) : 2083 - 2097
[44] Darolutamide plus androgen-deprivation therapy: propensity score matching of ARASEC and historic clinical trial patients
McKay, Rana R.
Ross, Ashley E.
Preston, Mark A.
Gregg, Justin R.
Salami, Simpa S.
Littleton, Natasha
Constantinovici, Niculae
Srinivasan, Shankar
Verholen, Frank
Shore, Neal D.
FUTURE ONCOLOGY, 2025, : 1365 - 1375
[45] Androgen deprivation therapy for the treatment of prostate cancer: a focus on pharmacokinetics
Polotti, Charles F.
Kim, Christopher J.
Chuchvara, Nadiya
Polotti, Alyssa B.
Singer, Eric A.
Elsamra, Sammy
EXPERT OPINION ON DRUG METABOLISM & TOXICOLOGY, 2017, 13 (12) : 1265 - 1273
[46] Intermittent Androgen Deprivation Therapy: Conventional Wisdom versus Evidence
Tombal, Bertrand
EUROPEAN UROLOGY, 2009, 55 (06) : 1278 - 1280
[47] Effect of Androgen Deprivation Therapy on Metabolic Complications and Cardiovascular Risk
Melloni, Chiara
Nelson, Adam
JOURNAL OF CARDIOVASCULAR TRANSLATIONAL RESEARCH, 2020, 13 (03) : 451 - 462
[48] Molecular Imaging Assessment of Androgen Deprivation Therapy in Prostate Cancer
Jadvar, Hossein
Colletti, Patrick M.
PET CLINICS, 2022, 17 (03) : 389 - 397
[49] Polymorphisms in androgen metabolism genes with serum testosterone levels and prognosis in androgen-deprivation therapy
Shiota, Masaki
Endo, Satoshi
Fujimoto, Naohiro
Tsukahara, Shigehiro
Ushijima, Miho
Kashiwagi, Eiji
Takeuchi, Ario
Inokuchi, Junichi
Uchiumi, Takeshi
Eto, Masatoshi
UROLOGIC ONCOLOGY-SEMINARS AND ORIGINAL INVESTIGATIONS, 2020, 38 (11) : 849.e11 - 849.e18
[50] Evaluating Intermittent Androgen-Deprivation Therapy Phase III Clinical Trials: The Devil Is in the Details
Hussain, Maha
Tangen, Catherine
Higano, Celestia
Vogelzang, Nicholas
Thompson, Ian
JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (03) : 280 - U147

← 1 2 3 4 5 →